Multiple sclerosis (MS) remains one of the leading causes of neurological disability in young adults, affecting nearly three million people globally. While current treatments have made significant strides in slowing the disease’s progression by suppressing the immune system, they do not address the core problem: the permanent damage to nerve tissue left behind.
A new doctoral thesis from the University of Helsinki suggests a potential breakthrough. Researchers have identified two distinct experimental drug molecules that successfully triggered the regrowth of myelin—the protective coating essential for nerve communication—in disease models. This marks a significant shift in strategy: moving from merely managing symptoms and inflammation to actively repairing neural damage.
The Critical Gap in Current MS Treatment
To understand why this research matters, it is necessary to look at how MS operates. The disease occurs when the immune system mistakenly attacks myelin, disrupting nerve signaling in the brain and spinal cord. As this damage accumulates, patients experience a range of debilitating symptoms, from blurred vision and chronic fatigue to severe mobility issues.
Current medications are designed to reduce excessive immune activity. However, they do not fix existing nerve damage. This limitation is particularly critical for patients with progressive MS, where injury builds gradually over years. For decades, scientists have sought ways to restart remyelination —the natural repair process where damaged myelin grows back. Despite numerous attempts, every drug candidate tested for this purpose has failed.
A major obstacle has been the central nervous system itself. In later stages of MS, the tissue develops local conditions that actively block repair mechanisms, creating a hostile environment for recovery.
Two Distinct Paths to Repair
Tapani Koppinen, working under the supervision of Associate Professor Merja Voutilainen, identified two separate strategies to overcome these barriers. Although the drugs work through completely different mechanisms, they achieved strikingly similar results: strong remyelination and reduced neuroinflammation.
1. Blocking Cellular Stress Responses
The first approach targets a specific stress response inside brain cells. In areas damaged by MS, this response remains constantly overactive, effectively stopping repair-promoting cells from doing their job.
By using a new drug molecule to block this mechanism, the researchers observed that remyelination increased significantly and occurred faster in brain tissue showing MS-like damage. This finding was published in the journal Molecular Therapy in February 2025.
2. Modifying Scar Tissue
The second strategy addresses the physical barriers to repair. When myelin is damaged, scar tissue often develops around the injured area, creating a physical obstacle that prevents nerve recovery.
The second drug molecule works by altering the makeup of this scar tissue, effectively clearing the path for neuronal recovery. This approach was detailed in an article published in Neuropharmacology in November 2025.
From Laboratory to Clinic: The Road Ahead
While these findings are promising, it is crucial to note that the results so far come from laboratory animals and cell models. Human MS involves more complex tissue conditions than those seen in animal studies.
Two significant challenges remain for clinical application:
* Human Complexity: The drug molecules must still be tested for effectiveness and safety in humans.
* The Blood-Brain Barrier: The brain is protected by a barrier that prevents many substances from entering. However, the researchers demonstrated that both molecules successfully reached the central nervous system in laboratory animals, a promising sign for future development.
“The goal is to enable the molecules we have developed to reach clinical trials, which could one day produce the first drugs that enhance remyelination in MS,” says Koppinen. “In the meantime, our findings can help in investigating the pathogenic mechanisms of MS that inhibit remyelination.”
Conclusion
This research represents a pivotal step toward treating the root cause of disability in multiple sclerosis rather than just its immune triggers. By demonstrating that two different molecular approaches can bypass the body’s natural blocks to repair, scientists have provided a viable roadmap for future therapies. While clinical trials are still years away, the potential to restore nerve function offers new hope for millions of patients living with progressive neurological damage.
